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 The tumor microenvironment is an area of intense interaction between normal and 
malignant cells.  Factors and cell types within this environment can play a crucial role in 
the progression or regression of the tumor.  Of primary interest are tumor-infiltrating T 
lymphocytes, which have been shown to have a key role in modifying the dynamics of 
the tumor microenvironment to promote or prevent tumor growth.  While there is much 
in vitro and in vivo evidence for a modification of the tumor infiltrating T cell population 
toward a pro-tumor environment, what induces these changes within the tumor 
microenvironment has remained elusive.  Our lab previously identified a role for the 
Inhibitor of Apoptosis protein Survivin as a secreted protein in the extracellular milieu, 
where it is capable of entering malignant cells and inducing a more aggressive phenotype.  
We hypothesized that tumor-secreted Survivin could be responsible for modulation of T 
lymphocytes in the tumor microenvironment.  We first isolated tumor released Survivin 
and confirmed it’s ability to be taken up by T cells as it is by malignant cells by confocal 
microscopy, flow cytometry and Western blotting.  Subsequently, we evaluated 
Survivin’s affect on T cell proliferation and found that tumor-released Survivin impairs T 
cell expansion, but does not alter its activation after exposure to appropriate stimuli.  
Assessment  of phenotypic changes within the cytotoxic and helper T lymphocyte 
xiv 
populations showed an increase in anti-inflammatory type 2 T cells and a reduction in 
type 1 T cells, which correlates to what has been observed in cancer patients.  Although 
often modified in the tumor microenvironment in patients, we did not observe and 
changes in regulatory T cells or Th17 cells in the presence of Survivin.  The results of 
this study provide evidence of Survivin’s role as an extracellular mediator of the tumor 
microenvironment, specifically its role in inducing a pro-tumor type 2 T cell population. 
 
1 
CHAPTER ONE 
INTRODUCTION 
Cancer 
Characteristics of Cancer Cells 
Cancer is a complex disease involving the accelerated and uncontrolled 
proliferation of abnormal cells that invade normal tissues.  While each type of cancer has 
different morphology, treatment and prognosis, several key features remain common 
throughout.  Six hallmarks were originally described by Hanahan and Weinberg in 2000, 
most of them involving molecular changes within cancer cells themselves (Figure 1.1).  
The definition of these features and their consolidation into one picture of cancer 
provided a model through which cancer progresses, eventually gaining these functions to 
reach the malignant state (Hanahan D and Weinberg RA 2000). 
The first of these hallmarks is the ability of cancer cells to replicate without limit, 
providing them with a never-ending proliferative capacity (Hanahan D and Weinberg RA 
2000).  While normal human cells have a replicative capacity of approximately 60-70 
divisions, malignant cells frequently exceed this limit, providing enough cells to form a 
tumor despite death of many of the pre-malignant cells along the way (Wyllie AH et al. 
1980; Bergers G et al. 1998).  This function of cancer cells to continue to divide past the 
typical threshold of normal cells was found to be aided by induction of telomere-
lengthening functions within these cells.  In a normal cell, the chromosome ends, or 
telomeres, shorten every time the DNA is replicated, until eventually the ends are 
degraded to the point of inducing apoptosis of the cell (Counter CM et al. 1992).  By 
upregulating factors that preserve telomere length (telomerase, ALT) the normal 
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proliferative capacity can be greatly exceeded by the malignant cell, resulting in tumor 
formation (Hanahan D and Weinberg RA 2000). 
The next two hallmarks go hand-in-hand to push the unrestrained proliferation 
allowed by the telomere lengthening mentioned previously: 1. Self-sufficiency in growth 
signals and 2. Insensitivity to anti-growth signals.  In the normal cell, growth is only 
induced when a need of the body requires it.  Some cell populations, like hematopoietic 
cells and gastric epithelial cells, replicate frequently due to wear and tear, while others 
replicate in the context of a specific need or after injury.  The promotion of this renewal 
is mediated by growth factors and mitotic signals transmitted through surface and 
intracellular receptors (Fedi P et al. 1997).  On the opposing side, anti-growth signals in 
the extracellular matrix and milieu prevent the proliferation of cells when not needed as 
well as excessive growth of cells after the necessary divisions have occurred by inhibiting 
the cell cycle.  Malignant cells alter both sides of this control mechanism to allow their 
unrestrained growth.  By inducing their own mitotic signals by either production of 
growth factors (PDGF, TGF-α) or altering the receptor-signaling cascade (Her2/neu, Bcr-
Abl) they can continue to proliferate even when exogenous growth factors have been 
withdrawn.  Additionally, by disrupting normal pathways that block the cell cycle, such 
as the retinoblastoma (pRB) and p15INK4B pathways, their endogenous growth factors 
push forward unchecked (Fynan TM and Reiss M 1993; Zuo L et al. 1996; Datto MB et 
al. 1997). Throughout the process of DNA replication and cellular proliferation, errors 
frequently occur that must be detected by the cell to maintain cellular integrity (Hanahan 
D and Weinberg RA 2000).  Upon detection, cells are given the chance to repair the 
mistakes and continue their division or are forced to die if the errors cannot be corrected.   
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Figure 1.1. The hallmarks of cancer.  From Hanahan and Weinberg 2000 and 2011, a 
schematic of the original (top) and emerging (bottom) characteristics of cancer. 
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The rapid and uncontrolled proliferation provided by the hallmarks we have 
discussed thus far provide many opportunities for error that would likely lead to 
apoptosis in the normal cell.  To prevent the likely death that would occur from 
replication infidelity in the malignant cell mechanisms to inhibit apoptosis are necessary. 
It has been stated that evasion of apoptosis is the largest barrier a cancer cell must 
overcome, as studies have shown that induction of the previously mentioned hallmarks 
alone result in the apoptosis of a large proportion of the cells (Kerr JF et al. 1972; 
Bergers G et al. 1998). The evasion of apoptosis is mediated by multiple factors within 
the cell including the Inhibitor of Apoptosis (IAP) protein and Bcl-2 family members 
(Hanahan D and Weinberg RA 2000).  By interfering with the caspase machinery and 
mitochondrial-mediated death anti-apoptotic molecules can prevent death of malignant 
cells in response to replicative errors and cellular stressors.  
The final two hallmarks are vital to the advancement of malignancy past the point 
of a small focal lesion.  To continue its growth the tumor must have access to nutrients 
and the ability to move past tissue barriers.  The angiogenic potential allows for the tumor 
to maintain access to a nutrient blood supply by extending vessels and inducing new 
vessel growth into the tumor mass (Bergers G et al. 1998; Hanahan D and Weinberg RA 
2000).  This is primarily mediated by increased cancer cell production of pro-angiogenic 
vascular endothelial growth factor (VEGF) and fibroblast growth factors (FGF1/2) and 
reduced production of anti-angiogenic factors thrombospondin-1 and β-interferon 
(Bergers G et al. 1998).  With a nutrient supply available, the only remaining barrier to 
tumor growth is the boundaries of the tissue compartment it is contained within.  Through 
production of matrix metalloproteinases (MMPs) and decreasing cell-cell adhesion 
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molecules like E-cadherin, cancer cells can move away from the tumor and past the 
basement membrane barrier to invade nearby tissues as well as metastasize to distant 
locations (Coussens LM and Werb Z 1996; Bergers G and Coussens LM 2000).  This 
metastatic function is part of what makes treatment of cancer incredibly difficult, as 
simple surgical techniques cannot be used systemically to eradicate the malignancy. 
As research in the field of cancer progressed, an updated version to this seminal 
review of cancer was released (Hanahan D and Weinberg RA 2011).  In 2011, Hanahan 
and Weinberg released “Hallmarks of Cancer: The Next Generation,” bringing several 
new players to the forefront of the cancer research world (Figure 1.1).  Several of these 
characteristics revolve around the interaction of the tumor and normal cells within the 
tumor microenvironment. 
 
The Tumor Microenvironment 
The Role of Fibroblasts 
Within the body of the tumor there are a variety of cell types, both malignant and 
normal and as with normal tissue biology it is critical to understand the interactions 
between the variety of cellular players to understand how it functions.  The presence of 
fibroblasts, endothelial cells and vessels are utilized by the tumor for protection, structure 
and nutrient support (Hanahan D and Weinberg RA 2011).  Fibroblasts play a vital role in 
normal tissues by production of the extracellular matrix and its ground substance and 
through the production of cytokines (Whiteside TL 2008).  They are also crucial to 
proper wound healing, with fibroblasts and myofibroblasts initiating wound contracture 
and closure.  In malignancy, fibroblasts help form the structural foundation for the tumor.  
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Additionally, myofibroblasts, which normally make up only a small portion of normal 
tissue structure, are increased in tumors.  Since myofibroblasts are also increased in 
chronic inflammation-induced fibrosis, it is thought that inflammation in the tumor 
microenvironment increases the proportion of myofibroblasts (Liao Y et al. 2007; 
Whiteside TL 2008).  The importance of this increase in myofibroblasts has been 
demonstrated in their ability to enhance tumor metastatic and angiogenic potential (De 
Wever O et al. 2004; Karnoub AE et al. 2007).   
 
Immune Cells 
The tumor microenvironment is also home to a large number of immune cells, the 
role of which has been intently investigated.  The role of immune cells in the progression 
or prevention of cancer and within the tumor microenvironment has been intently 
debated.  Both anti-tumor and pro-tumor effects have been characterized and it now 
appears it is the balance of these factors and the tumor’s ability to modulate this balance 
that determines what part the immune system will play in the development in cancer. 
 
Macrophages 
 Macrophages are myeloid-derived immune cells that function to phagocytose and 
kill pathogens and present their antigens to the adaptive immune system.  Within the 
tumor microenvironment macrophages are reprogrammed so that instead of activating the 
adaptive immune response, they quench it (Liao Y et al. 2007).  This can be explained by 
the dual nature of macrophages.  As is seen in many immune cell populations, 
macrophages exist as either M1 or M2 cells.  The type 1 or M1 phenotype is primarily 
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pro-inflammatory and has an excellent capacity for killing cancer cells, presenting their 
antigens and activating an adaptive immune inflammatory response against the tumor 
(Liao Y et al. 2007).  These functions are mediated by production of tumor necrosis 
factor alpha (TNF-α) and nitric oxide (NO).  However, because these functions require 
the presence of oxygen, within the hypoxic tumor microenvironment, they are readily 
diminished.  The type 2 or M2 phenotype of macrophages plays a more permissive role in 
the tumor microenvironment.  Their production of growth factors such as VEGF promote 
tumor angiogenesis and sustenance (DeNardo DG et al. 2009).  Release of IL-10 and 
prostaglandins by M2 cells diminishes the immune response by Natural Killer (NK) cells 
and inflammatory T lymphocytes, providing a safe environment for the tumor (Liao Y et 
al. 2007; DeNardo DG et al. 2009). 
 
Dendritic Cells 
 Dendritic cells (DCs) are an important driving force in the immune response as 
they are the most potent antigen presenting cells.  The induction of an immune response 
or the production of anergy in adaptive immune cells is partly dependent on their 
maturity, with immature cells producing anergy and mature cells potently activating the 
adaptive immune response (Liao Y et al. 2007).  Mature dendritic cells predominate in 
most tissues in order to provide activation of the adaptive immune system upon detection 
of a pathogen, however, within the tumor microenvironment there is a preponderance of 
immature DCs, while mature DCs are a rarity.  Increased amounts of VEGF can impair 
DC maturation and it is suspected that other cytokines produced in the tumor 
microenvironment play an additional role (Liao Y et al. 2007). 
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B Lymphocytes 
 The role of B lymphocytes has been investigated in several different cancer types 
including breast, colorectal, melanoma and ovarian cancers (Hansen MH et al. 2002; 
Galon J et al. 2006; Milne K et al. 2009; Erdag G et al. 2012).  It is currently unclear if 
the predominant function of B cells in the tumor microenvironment is pro- or anti-tumor 
(Linnebacher M and Maletzki C 2012).  Studies in breast cancer has shown that greater 
than 40% of patients have anti-tumor antibody production by B cells that correlate to a 
more favorable outcome (Hansen MH et al. 2002; Kotlan B et al. 2005). Additionally, in 
lung and breast carcinoma, antibodies produced by B cells in the tumor 
microenvironment may aid in tumor elimination (Kotlan B et al. 2005).  In contrast, 
studies in mice have shown that B cells may interfere with T cell eradication of tumor 
cells (Liao Y et al. 2007).  Determining the precise role of B cells in other malignancies 
is an area of intense research with many questions left to be answered, including if they 
primarily promote or hinder cancer progression.     
 
T Lymphocytes 
 The role of T lymphocytes in malignancy is complicated at best.  Multiple T cell 
phenotypes have been shown to play a role in the progression or elimination of cancer, 
depending on the cancer type (Nakayama H et al. 2000; Chikamatsu K et al. 2007; 
Schreck S et al. 2009).  Four main players have emerged in the T cell reaction to 
malignancy, and the balance of them can alter tumor progression (Figure 1.2).  They 
include Type 1 and Type 2 T lymphocytes, regulatory T lymphocytes (Tregs) and IL-17 
secreting T lymphocytes (Th17) (Zhu J and Paul WE 2008; Kryczek I et al. 2009). 
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Type 1 and Type 2 T Lymphocytes.  Type 1 T cells are comprised of both CD4+ 
helper and CD8+ cytotoxic populations, Th1 and Tc1, respectively.  The defining 
characteristic of these cells is their cytokine profile, which consists of tumor necrosis 
factor alpha (TNF-α), gamma interferon (IFN-γ), and interleukin 2 (IL-2) (Woodland DL 
and Dutton RW 2003).  The type 1 T cell cytokine IFN-γ is vital to the anti-tumor 
response as it recruits and activates macrophages, as well as increasing the cytotoxic 
response by CD8+ T cells.  Mice deficient in IFN-γ have been shown to spontaneously 
develop tumors and have poor tumor clearance, illustrating the importance of IFN-γ in 
anti-tumor immunity (Riemensberger J et al. 2002).  Production of IL-2 by type 1 cells 
increases the proliferation of nearby T cells, aiding the immune response by inducing 
clonal expansion of tumor-reactive cells.  
 The antagonists of type 1 cells are the type 2 Tc2 and Th2 cells, which release IL-
4, IL-5, IL-6, IL-10 and IL-13 (Zhu J and Paul WE 2008).  Type 2 cytokines prevent the 
differentiation of naïve T cells into type 1 cells and oppose the functions of type 1 
cytokines.  IL-10 decreases the cytotoxic response by decreasing antigen presentation by 
macrophages to Th1 cells, while IL-4 leads to decreased type 1 cell differentiation and 
IFN-γ production (Wurtz O et al. 2004).  In cancer, IL-4 has been shown to prevent 
apoptosis of malignant cells, as well as increase the metastatic potential of breast cancer 
cells through polarization of infiltrating macrophages (DeNardo DG et al. 2009). 
Peripheral blood and intratumoral T cells from cancer patients frequently have an 
imbalance in type 1 and type 2 T cell populations (Filella X et al. 2000; Nakayama H et 
al. 2000; Mainou-Fowler T et al. 2003; Murakami H et al. 2004; Sharma A et al. 2010). 
Type 1 responses are typically decreased with a concomitant increase in type 2 cell 
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numbers and cytokine levels. The potential for metastasis and angiogenesis is increased 
by the presence of IL-4 and IL-6, respectively, both of which are produced by type 2 T 
cells (Naldini A et al. 2003).  This shift in the balance of type 1 and type 2 T cells has 
been correlated to poor disease progression, as the anti-tumor response is inhibited and a 
pro-tumor environment is created. 
Regulatory T Cells.  Characterized as CD4+CD25+CD127lowFoxp3+, regulatory 
T cells (Tregs) are important in preventing immune responses to autoantigens and over-
activation of the inflammatory response (Liu W et al. 2006).  Treg cells have been 
implicated in promoting tumor growth by suppressing activation of tumor-specific 
cytotoxic T cells due to their expression of auto-antigens by production of Transforming 
Growth Factor-β (TGF-β), cytolysis, and the induction of anergy (James E et al. 2010).  
In addition to suppressing the immune response, Tregs are also able to promote cancer 
stem cells.  The regulation of cancer stem cells by Tregs is mediated by secretion of 
TGF-β, which promotes microsphere formation (Penuelas S et al. 2009).  As with type 2 
T cells, increased numbers of Tregs within the tumor correlates with poor prognosis and 
decreased responsiveness to immunotherapies (Chattopadhyay S et al. 2006; Clarke SL et 
al. 2006; Chikamatsu K et al. 2007; James E et al. 2010; Sellitto A et al. 2011; 
Yamagami W et al. 2011).  
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Table 1 
Cytokines released by type 1 and type 2 T cells and their functions in malignancy. 
 Cytokine Function 
Type 1 
Interferon-γ 
Differentiation of naïve T cells into type 1 T 
cells 
Inhibition of the type 2 T cell response 
Increased cytotoxic CD8+ T cell response 
Activation of macrophages 
Interleukin-2 
Induction of T cell proliferation 
Clonal expansion of anti-tumor T cells 
Type 2 
Interleukin-4 
Inhibition of the type 1 T cell response 
Reduced interferon-γ production  
Prevention of cancer cell apoptosis 
Polarization of tumor-infiltrating macrophages 
Increased metastatic potential 
Interleukin-6 Increased angiogenic potential  
Interleukin-10 
Differentiation of naïve T cells into type 2 T 
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Figure 1.2. The divisions of T cell response.  A naïve T cell can become a type 1 
(orange), type 2 (blue), Treg (purple) or Th17 (green) cell based on the cytokines it is 
exposed to when activated.  Upon differentiation, each cell type secretes a characteristic 
cytokine profile. 
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Th17 Cells.  Pro-inflammatory CD4+ Th17 cells produce IL-17 to recruit 
neutrophils and induce the production of pro-inflammatory factors in immune cells 
(Kryczek I et al. 2009; Maniati E et al. 2010; Reynolds JM et al. 2010).  The role of 
Th17 cells in cancer is still unclear.  The inflammatory Th17 response correlates with 
poor disease outcome in prostate, head and neck and colorectal cancer.  This is 
hypothesized to be due to production of the anti-inflammatory mediator prostaglandin-E2 
(PGE2) and pro-angiogenic hypoxia-inducible factor 1-alpha (HIF1α) (Penuelas S et al. 
2009).  However, IL-17 knockout mice exhibited increased susceptibility to metastasis of 
colon cancer MC38 cells, demonstrating a possible anti-tumor function of Th17 cells 
(Maniati E et al. 2010).  Th17 cells reduce Treg cell numbers by lowering TGF-β release 
and increase cytotoxic T cell function by secretion of IL-21 (Penuelas S et al. 2009).  
Although the precise mechanism of Th17 induction is still unclear, it appears that in 
malignancies initiated by inflammation, high numbers of Th17 correlate with poor 
prognosis due to their role in the induction of inflammation and angiogenesis (Yang ZZ 
et al. 2009).  In tumors that were not initiated by an inflammatory response, Th17 cells 
may be beneficial in activating a cytotoxic immune response to eradicate the tumor 
(Yang ZZ et al. 2009). 
Although all of these changes that occur to the immune cells in the tumor 
microenvironment have been documented in patient and animal models, the precise 
mechanism that causes them is not well understood.  While we have evidence for a role 
for hypoxia in skewing the tumor-infiltrating macrophage population, the same cannot be 
said for T cells.  There are several hypotheses, one of which is the idea that one or more 
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factors released by the tumor itself is likely a cause for this change in the T lymphocyte 
population.   
 
Survivin 
Survivin as a Member of the Inhibitor of Apoptosis Family 
 Survivin is a 142 amino acid protein and member of the Inhibitor of Apoptosis 
(IAP) protein family.  As a member of this family it contains a baculoviral inhibitor of 
apoptosis repeat (BIR) domain, so named because the original members of the IAP 
family (Cp-IAP and Op-IAP) were found to use this domain to bind and inhibit caspases 
in baculoviruses (Crook NE et al. 1993; Clem RJ and Miller LK 1994).  In humans, 
Survivin and its other IAP family members (XIAP, c-IAP1, c-IAP2, and NAIP) have 
been shown to inhibit programmed cell death (Liston P et al. 1996; Ambrosini G et al. 
1997).  However, unlike its other family members, Survivin does not contain the typical 
RING zinc finger or the caspase-recruitment domain (CARD) necessary for their anti-
apoptotic function.  Despite lacking these domains, Survivin is capable of preventing 
apoptosis signaled by TNF-α and Fas/FasL.   
 
Anti-Apoptotic Function and Role in Cancer 
 Members of the IAP family typically prohibit programmed cell death through 
direct interaction with caspases, particularly activated caspase-3 and -7 (Deveraux QL et 
al. 1997; Roy N et al. 1997).  With Survivin, the mechanism by which it inhibits 
apoptosis is not as clear.  Some research has suggested that Survivin inhibits caspases-3 
and -7 directly (Tamm I et al. 1998; Shin S et al. 2001), while others have suggested that 
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there is no interaction with caspase-3 (Banks DP et al. 2000).  Still others have suggested 
Survivin’s anti-apoptotic effect is through inhibition of caspase-9 due to its ability to bind 
caspase-9 on the mitotic spindle and its ability to prevent staurosporine-induced death 
(O'Connor DS et al. 2000; Chandele A et al. 2004).  While the precise mechanism by 
which Survivin prevents cell death is uncertain, it is known that Survivin can prevent 
Bax- and Fas-induced apoptosis (Ambrosini G et al. 1997; Tamm I et al. 1998).  
Survivin’s overexpression has been documented in most, if not all, types of 
cancer, and high levels of it have been linked to poorer prognosis in small cell lung 
cancer, non-small cell lung cancer, hepatocellular carcinoma, and colorectal carcinoma 
(Kawasaki H et al. 1998; Monzo M et al. 1999; Ikeguch M et al. 2002; Ikehara M et al. 
2002).  Survivin expression is also detectable in normal fetal development.  In situ 
hybridization in chick embryos found that Survivin is expressed in the majority of fetal 
tissues, including lung, kidney and dorsal root ganglion.  In mouse embryos, Survivin 
expression was ubiquitous throughout all tissues(Adida C et al. 1998).   However, after 
fetal development Survivin expression is dramatically reduced or absent in mature human 
tissues.  It is likely that through demethylation of the survivin gene promoter, malignant 
and pre-malignant cells are able to overexpress Survivin and evade apoptosis to go on to 
produce disease (Hattori M et al. 2001). 
 
Survivin’s Function in Cell Cycle Regulation 
      Survivin expression can be detected both in the cytoplasm and nucleus throughout 
the cell cycle, but its expression peaks during the G2/M phase of the cell cycle (Li F et al. 
1998).  This nuclear and cell-cycle regulated expression led to the idea that Survivin may 
16 
play a role in cell proliferation.  Indeed, upon further investigation it was found that 
Survivin is a component of the chromosomal passenger complex (CPC) along with 
Aurora-B and Borealin (Lens SM et al. 2006; Canovas PM and Guadagno TM 2007).  Its 
function in the cell cycle includes organization of the central spindle and correction of 
spindle attachment errors to allow cell division.  This function is seen not only in 
malignant cells, but also in T lymphocytes.  Upon T cell activation and clonal expansion, 
Survivin is upregulated to aid in the rapid proliferation that occurs (Song J et al. 2005).  
 
Survivin in Immune Cell Modulation 
 Survivin has a well-documented role in malignancy, but recent research shows it 
has an additional function in inflammation and autoimmunity.  The amount of Survivin in 
the synovial fluid of rheumatoid arthritis patients has been correlated to a more severe 
disease progression (Bokarewa M et al. 2005).  It is thought that synoviocytes, which 
resemble fibroblasts, may be the source of Survivin production in patients with 
rheumatoid arthritis (Ahn JK et al. 2010).  Additionally, when recombinant Survivin was 
added to immune cell cultures, it was found to upregulate adhesion molecules CD11b and 
CD11c on granulocytes and monocytes.  Similar adhesion molecule profiles were 
observed in rheumatoid arthritis patients with high levels of synovial fluid Survivin 
(Mera S et al. 2008). 
 
Survivin as an Exosomal Protein 
 In addition to its cytosolic (Fortugno P et al. 2002), nuclear (Fortugno P et al. 
2002) and mitochondrial (Dohi T et al. 2004) localization, Survivin has also been found 
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in the extracellular milieu and in exosomes secreted by cancer cells (Khan S et al. 2009; 
Khan S et al. 2011).  Survivin has been shown to colocalize with Hsp70 in exosomes 
isolated from cancer cell-conditioned medium, demonstrating a novel pool of Survivin.  
Extracellular and exosomal Survivin has been shown to be taken up by malignant cells, 
resulting in altered function and increased aggressiveness (Khan S et al. 2009).  Upon 
uptake into cancer cell lines, extracellular Survivin is able to induce proliferation and 
invasive potential as well as increase their resistance to UV radiation and chemotherapy.  
The exact mechanism that allows localization of Survivin into the exosome and its 
subsequent uptake into nearby malignant cells is not completely understood and is 
currently under investigation.  However, it has been shown that increased cellular stress 
by sublethal doses of proton radiation enhances packaging of Survivin in exosomes, 
resulting in increased release of Survivin into the tumor microenvironment (Khan S et al. 
2011).  
Purpose of Study 
While the role of T cells in cancer and their phenotypic alteration has been 
thoroughly assessed, the driving force behind this alteration is still not clear.  Because of 
Survivin’s extracellular release by exosomes and its ability to modulate leukocytes in 
autoimmune disease, we propose that Survivin within the tumor microenvironment could 
modify the T cell response to promote tumor growth.  In order to evaluate this hypothesis 
we first sought to confirm that Survivin could be taken up by T lymphocytes in a similar 
manner as observed in malignant cells.  Secondly we defined the effect of Survivin on 
cytotoxic CD8+ T lymphocyte cytokine release and cytotoxic function.  Lastly, we 
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evaluated Survivin’s ability to skew normal T lymphocytes toward a type 2 phenotype, 
which would aid cancer cells by decreasing anti-tumor inflammation.   
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CHAPTER TWO 
ISOLATION AND T CELL UPTAKE OF TUMOR-RELEASED 
SURVIVIN 
Introduction 
 Survivin is a member of the Inhibitor of Apoptosis (IAP) protein family that has 
been shown to prevent cell death induced by the Fas/FasL, Bax and caspase 
pathways(Ambrosini G et al. 1997; Tamm I et al. 1998).  This multi-functional protein 
also acts as a cell cycle regulator and is expressed in the G2/M phase to aid in 
proliferation.  The proliferative and anti-apoptotic bi-functionality of Survivin makes it 
an essential component in the life of a cancer cell.  Survivin has been found in the 
cytosol, mitochondria and nucleus of the cell (Fortugno P et al. 2002; Dohi T et al. 2004), 
as well as extracellularly in exosomes (Khan S et al. 2009; Khan S et al. 2011).  The 
packaging of Survivin into exosomes allows its release into the tumor microenvironment 
where it is taken up by other cancer cells (Khan S et al. 2009; Khan S et al. 2011).  This 
uptake of Survivin by malignant cells results in increased proliferative and invasive 
potential as well as resistance to chemotherapy (Khan S et al. 2009).   
In addition to cancer cells, fibroblasts and immune cells populate the tumor 
microenvironment.  While cancer cells take up extracellular Survivin, normal fibroblasts 
and epithelial cells, which normally do not express Survivin, show no uptake (Khan S et 
al. 2009).  Some normal cells, such as T lymphocytes, do express low levels of Survivin 
causing us to question the ability of these normal cells to take up Survivin from the 
extracellular space.  T lymphocytes are found abundantly within the tumor 
microenvironment, and frequently are modulated by the tumor to be less cytotoxic, 
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preventing tumor attack.  If Survivin is taken up from the extracellular space by T 
lymphocytes it could point towards a role for Survivin in T lymphocyte modulation in the 
tumor microenvironment.   
We isolated tumor-released Survivin from conditioned medium using the pOZN-
Survivin-WT cell line, which secretes a FLAG-HA-tagged Survivin.  Survivin was pulled 
down using dual-affinity immunoprecipitation and quantified by Enzyme-Linked 
Immunosorbant Assay (ELISA).  Evaluation of uptake showed that both malignant cells 
and T lymphocytes could indeed take up the purified Survivin.  Additionally, because 
excess Survivin was observed to be toxic to normal T lymphocytes in large amounts, we 
determined the sublethal dose of our purified Survivin that could be used in our future 
studies.  The results in this chapter provided the preliminary results that lead us to our 
findings in the subsequent chapters. 
 
Results & Discussion 
Uptake of Purified FLAG-HA-Survivin in T Lymphocytes 
Isolation and Quantification of Survivin from Conditioned Medium 
 We isolated a FLAG-HA tagged Survivin from the conditioned medium of HeLa-
S cells.  This was accomplished using the pOZN-Survivin-WT cell line; a cervical 
carcinoma HeLa-S cell line engineered to overexpress a FLAG-HA-tagged wild-type 
Survivin (Khan S et al. 2009).  The pOZN-Survivin-WT cells were grown in a bioreactor 
and the conditioned medium collected after 24 hours.  After eliminating cellular debris by 
serial centrifugation, Survivin was isolated from the conditioned medium by 
immunoprecepitation (IP) using anti-FLAG and anti-HA antibodies.  Quantification of 
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the purified Survivin was done using a Survivin-specific ELISA and found to be 1.25 
pg/μl.   
While we had already shown that Survivin from conditioned medium could be 
taken up by cancer cells (Khan S et al. 2009), we needed to evaluate their ability to take 
up our purified Survivin.  HeLa-S cells were cultured with various concentrations of 
isolated FLAG-HA-Survivin or conditioned medium and Survivin uptake evaluated by 
immunofluorescence microscopy.  Figure 2.1 shows that at 0.625-12.5 pg/ml there is 
visible uptake of FLAG-HA-Survivin by anti-HA staining, comparable to what was seen 
in cells cultured with conditioned medium. 
 
Isolation of T Lymphocytes and Determination of Sublethal Dose 
 Due to the fragile nature of primary T lymphocytes, we sought to determine what 
dose of extracellular Survivin could be used without causing significant toxicity.  CD3+ T 
lymphocytes were isolated from the peripheral blood of normal volunteers by 
centrifugation on Ficol-Hypaque  solution, followed by magnetic separation.  Peripheral 
blood mononuclear cells (PBMCs) were isolated from the buffy layer and incubated with 
biotinylated antibodies against CD3.  Using streptavidin magnetic beads the T 
lymphocytes were separated from other PBMCs on a magnetized column and then eluted.  
These cells were then cultured with 0-10 pg/ml FLAG-HA-Survivin and viability 
evaluated by 7-AAD staining and flow cytometry.  The percentage of cell death increased 
with increasing doses of Survivin as shown in Figure 2.2.  Based on this data we chose to 
use 1.25 pg/ml in our subsequent experiments.          
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Figure 2.1. Uptake of purified FLAG-HA-Survivin by HeLa-S cells.  FLAG-HA-
Survivin was isolated by immunoprecipitation from conditioned medium and added to 
cultured HeLa-S cells for 24 hours.  Uptake at various concentrations was evaluated 
using immunofluorescene microscopy.  Staining shows uptake at all concentrations 
equivalent to the conditioned medium positive control (Blue = DAPI; Red = HA). 
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Figure 2.2.  Analysis of T lymphocyte death with increasing Survivin concentration.  
Isolated T lymphocytes were incubated for 24 hours with FLAG-HA-Survivin at 
various concentrations.  Cells were analyzed for death by 7-AAD staining and flow 
cytometry and showed an increase in cell death with increasing concentrations of 
Survivin.  Gating scheme and percent dead cells are shown (*p< 0.05, *** p<0.001). 
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Evaluation of Survivin Uptake in T Lymphocytes 
To determine if T lymphocytes can take up extracellular Survivin as cancer cells 
do, our isolated CD3+ T lymphocytes were cultured with 1.25 pg/ml FLAG-HA-Survivin 
and evaluated for Survivin uptake by confocal microscopy as shown in Figure 2.3.  Due 
to the narrow ring of cytoplasm surrounding each cell, it was difficult to determine the 
location of Survivin by confocal microscopy alone.  The pyknotic staining of Survivin 
made it appear that it may be on the surface of the cell and not within the cytoplasm.  To 
further assess this, Survivin uptake was evaluated by immunofluorescence microscopy 
with β-actin colocalization.  As shown in Figure 2.4 there are areas of yellow staining 
where both the β-actin (red) and FLAG-HA-Survivin (green) are colocalized, as well as 
separate pyknotic green staining areas, showing that Survivin is both within the 
cytoplasm, as well as on the cell surface.   
Further characterization of this uptake was performed using flow cytometry by 
both surface and intracellularly staining for Survivin and HA from 0-720 minutes after 
the addition of extracellular Survivin (Figure 2.5A,B).  Beginning at 5 minutes, there is a 
similar amount of Survivin staining on the surface as well as intracellularly, followed by 
increased intracellular Survivin staining over time.  These results indicate an initial 
surface binding of Survivin on T lymphocytes and a subsequent entry into the cytoplasm 
of the cell.  Additionally, Western blot analysis of FLAG-HA-Survivin uptake in T 
lymphocytes showed that after entry into the cell, Survivin persists for at least 96 hours as 
demonstrated in Figure 2.5C. 
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Figure 2.3. Confocal microscopy of Survivin uptake by T lymphocytes.  T lymphocytes 
were incubated with FLAG-HA-Survivin for 24 hours and stained with anti-HA 
antibodies for confocal microscopy.  Images show 1 micron slices through the cells.  
Pyknotic FLAG-HA-Survivin staining is seen on the T lymphocytes (Blue=DAPI, 
Red=HA). 
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Figure 2.4. Colocalization analysis of Survivin uptake in T lymphocytes.  T lymphocytes 
were cultured with FLAG-HA-Survivin and stained for both FLAG and β-actin. White 
arrow shows yellow colocalization of β-actin and FLAG, demonstrating the Survivin is in 
the cytoplasm as well as on the surface (Blue=DAPI, Red= β-actin, Green=FLAG).
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Figure 2.5. Flow cytometric and Western analysis of Survivin uptake in T lymphocytes.  
A.  T lymphocytes were cultured with FLAG-HA-Survivin over time and analyzed for 
surface binding and intracellular uptake.  Some surface binding was observed throughout, 
while intracellular levels increased over time.  B.  Graphical representation of flow 
cytometry data (Mean Intracellular Fluorescence = Total Fluorescence – Surface 
Fluorescence).  C.  Western analysis of T lymphocytes shows that FLAG-HA-Survivin 
persists in the cells even up to 96 hours after removal from culture. 
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Conclusions 
 
The results of these studies show that indeed our purified FLAG-HA-Survivin can 
be taken up by malignant cells, just as is seen in conditioned medium.  Additionally and 
most importantly, FLAG-HA-Survivin is able to bind to the surface of T lymphocytes as 
well as enter into the cells.   This finding, along with the persistence of FLAG-HA-
Survivin within the lymphocytes for several days after incubation, points to a potential 
role for Survivin in immune evasion within the tumor microenvironment. 
 
Materials & Methods 
Collection of Conditioned Medium from pOZN-Survivin-WT Cells 
FLAG-HA-Survivin pOZN-Survivin-WT cells were grown in a 5L bioreactor at 
37C in Joklik medium supplemented with 10% FCS, L-glutamine and 
penicillin/streptomycin.  After 1 week of growth the conditioned medium was collected 
and centrifuged at 3,000 x g for 5 minutes at 4C to remove cells.  The supernatant was 
then centrifuged at 10,000 x g for 10 minutes at 4C to remove cellular debris. 
 
Isolation of FLAG-HA-Survivin from Conditioned Medium 
Anti-FLAG beads (20 l/ml) were added to the centrifuged conditioned medium 
and rotated overnight at 4ºC. The beads were pelleted by centrifugation and Survivin 
eluted from the beads using FLAG peptides.  This process was repeated using anti-HA 
beads (20 l/ml).  Free FLAG and HA peptides were removed from the preparation by 
dialysis against a 10 mM HEPES buffer (pH 7.5) overnight at 4ºC.  The concentration of 
Survivin was 1.2 ng/ml as determined by ELISA (R&D Systems).  Synthesized FLAG 
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and HA peptides were added to 10mM HEPES buffer at a concentration of 1.2 ng/ml for 
use as a control. 
 
Culture and Treatment of HeLa-S Cells 
 HeLa-S cells were cultured in flasks in a 5% CO2 incubator with DMEM medium 
supplemented with 10% FCS, L-glutamine and penicillin/streptomycin.  To evaluate for 
purified Survivin uptake, cells were cultured with conditioned medium from pOZN-
Survivin-WT cells or with 0.0-12.5 pg/ml FLAG-HA-Survivin for 24 hours.    
 
Isolation of T Lymphocytes from Peripheral Blood 
Peripheral blood from normal, healthy donors was collected into potassium 
EDTA vacuettes as approved by the Institutional Review Board at Loma Linda 
University.  Peripheral blood mononuclear cells (PBMCs) were isolated from the buffy 
layer following centrifugation on a Ficoll-Hypaque gradient (GE Healthcare).  PBMCs 
were washed with cold Streptavidin Labeling Buffer (PBS with 2mM EDTA pH7.2) and 
stained with anti-human CD3 biotinylated antibodies (BioLegend) at 4°C.  Cells were 
again washed with cold Streptavidin Labeling Buffer and then incubated with 
Streptavidin magnetic microbeads. (Miltenyi Biotec)  After an additional wash the cells 
were added to a magnetic column and eluted from the CD3- cells.  The isolated CD3+ 
cells were cultured in R10 medium (RPMI supplemented with 10% FBS, L-glutamine, 
penicillin/streptomycin, and 0.1% 2-mercaptoethanol). 
 
 
30 
Immunofluorescence and Confocal Microscopy 
T lymphocytes or HeLa-S cells were cultured in 12-well plates in R10 or FLAG-
HA-Survivin medium.  Cells were harvested after 24 hours in culture, fixed with 3.7% 
paraformaldehyde and permeabilized with 0.1% PBS-saponin.  Cells were stained with 
anti-FLAG, anti-HA or anti-Actin primary antibodies and goat anti-mouse Alexa Fluor 
488 or goat anti-rabbit Alexa Fluor 555 secondary antibodies (Invitrogen).  Slides were 
imaged using the Olympus BX50 fluorescent microscope or Zeiss LSM 710 NLO laser 
scanning confocal imaging system, equipped with an Axio Observer Z1 inverted 
microscope.  
 
Flow Cytometry 
T lymphocytes were cultured in 96-well plates in R10 or FLAG-HA-Survivin 
medium at a concentration of 1x106 cells/ml.  Cells were harvested at 5, 15, 30, 60, 120, 
240, 360 and 720 minutes and stained for surface-bound or intracellular Survivin using 
rabbit anti-FLAG, goat anti-rabbit Alexa Fluor 488 secondary (Invitrogen, Carlsbad, 
CA), and anti-Survivin Alexa Fluor 647 antibodies (Cell Signalling, Danvers, MA).  For 
intracellular staining, cells were fixed and permeabilized using the eBioscience 
Fixation/Permeabilization Kit (San Diego, CA).  Cells were stained for T lymphocyte 
surface antigens with monoclonal antibodies against CD3, CD4, and CD8 (BioLegend, 
San Diego, CA).  Data was collected on the MACSQuant flow cytometer (Miltenyi 
Biotec, Auburn, CA) and analyzed with FlowJo analysis software.   
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Western Blotting 
For Western blots of Survivin uptake, T lymphocytes were cultured with FLAG-
HA-Survivin, harvested at 24, 48, 72, and 96 hours, and washed with PBS.  Whole cell 
lysates were prepared and separated using 12% Bis-Tris polyacrylamide gels run at 
60mA for 45 minutes.  Proteins were transferred onto nitrocellulose membranes at 
350mA for 75 minutes.  After blocking with Odyssey Blocking Buffer, membranes were 
probed using mouse monoclonal anti-FLAG (Invitrogen), rabbit polyclonal anti-Survivin 
(Novus Biologicals), and rabbit polyclonal anti-Actin (Cell Signalling).  Secondary IR-
Dye conjugated goat anti-rabbit and goat anti-mouse antibodies (LICOR) were utilized 
and bands detected using the Odyssey imaging system (LICOR).  
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CHAPTER THREE 
MODULATION OF T LYMPHOCYTE PROLIFERATION BY 
SURVIVIN 
Introduction 
 Humoral and adaptive immune functions are crucial in the prevention of many 
cancers.  Cytotoxic CD8+ T lymphocytes normally aid in the prevention of cancer by 
destroying abnormal or transformed cells (Rosenberg SA et al. 1998).  The failure of 
these responses have been implicated in the development and progression of many 
cancers, but is exemplified in cancers induced by viral infection such as Burkitt’s 
Lymphoma and nasopharyngeal carcinoma (Li J et al. 2007) and increased frequency of 
malignancy in immunocompromised individuals (Vajdic CM and van Leeuwen MT 
2009).  Progression of malignancy is in part dependent on the tumor’s ability to evade 
immune detection and cytolytic destruction by T lymphocytes (Hanahan D and Weinberg 
RA 2011).  Indeed, patients with ovarian cancer have significantly improved prognosis 
when the tumor microenvironment is well infiltrated with cytotoxic T lymphocytes and 
natural killer cells (Zhang L et al. 2003; Sato E et al. 2005).  However, induction of the T 
lymphocyte response does not always prevent progression of cancer, even in 
immunocompetent individuals.  The mechanisms by which this occurs have been 
investigated and linked to reduced induction of T lymphocytes in response to the tumor 
as well as T regulatory cell inhibition of the T lymphocyte response (Woo EY et al. 
2001).   
Due to Survivin’s critical role in cell proliferation, both in malignant cells and T 
lymphocytes (Altieri DC 2003; Song J et al. 2005), and our previous findings that tumor-
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released Survivin effects malignant cell proliferation, we sought to evaluate the effects of 
tumor-released Survivin on T lymphocyte activation and clonal expansion.  In order to 
determine the role of Survivin in the tumor immune response, we utilized our isolated 
and purified FLAG-HA-Survivin to evaluate T lymphocyte proliferation, activation and 
cytotoxic function.  We noted a reduction in T lymphocyte proliferation in the presence 
of tumor-released Survivin, while activation was not effected.  Together this data 
demonstrates a role for tumor-released Survivin in the impairment of the anti-tumor 
response. 
 
Results & discussion 
Reduced Proliferation in Survivin-Exposed T Lymphocytes 
To determine if Survivin uptake in T lymphocytes affects their ability to respond 
to activating stimuli, we analyzed their proliferation using the cell-cycle-associated 
nuclear antigen Ki-67 (Scholzen T and Gerdes J 2000), carboxyfluorescien succinymidyl 
ester (CFSE) reduction and BrdU incorporation assays.  T lymphocytes were isolated 
from healthy, cancer-free donors, stimulated with anti-CD3/CD28 T cell expansion beads 
and cultured in control medium, medium containing isolated FLAG and HA peptides, or 
medium containing tumor-released FLAG-HA-Survivin.  Expression of intracellular Ki-
67 was analyzed at 24, 48, 72 and 96 hours by flow cytometry.  Figure 3.1 shows a 
representative gating scheme for our flow cytometry data.  T cells were selected by 
positive CD3 staining and Figure 3.2A shows representative staining of Ki-67 at 72 hours 
post-stimulation.  At 72 and 96 h, Ki-67 expression was significantly decreased in both 
CD8+ and CD4+ T lymphocytes when cultured with FLAG-HA-Survivin compared to 
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Control and FLAG-HA only medium (Figure 3.2B).  This demonstrates decreased T cell 
proliferation in the presence of Survivin. 
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Figure 3.1.  Gating scheme for Ki-67 analysis.  A.  Lymphocytes were selected by their 
Forward and Side Scatter profiles.  B.  T lymphocytes were selected by positive 
staining for CD3.  Ki-67 expression was analyzed on both C. CD4 and D. CD8 stained 
populations. 
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Figure 3.2. Ki-67 expression in T lymphocytes  A.  Representative gating 
scheme of T lymphocyte Ki-67 expression.  B. Normal T lymphocytes have 
significantly decreased Ki-67 expression at 72 and 96 hours following 
incubation with cancer cell-released FLAG-HA-Survivin compared to control 
and FLAG-HA only medium.  *p<0.05, ***p<0.001. 
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To confirm these results we evaluated CFSE dilution in T lymphocytes.  CFSE is 
a cytosolic fluorescent dye used to detect proliferation, with a dilution of the dye 
observed with each cell division (Lyons and Parish, 1994).  If indeed Survivin is reducing 
proliferation in these cells, the CFSE fluorescence of cells stimulated in the presence of 
Survivin should be higher due to reduced dilution through proliferation compared to 
controls.  Helper and cytotoxic T lymphocytes were selected by CD4 and CD8 expression 
respectively and analyzed for CFSE fluorescence intensity (Figure 3.3).  CFSE staining 
showed dilution in response to stimulation in Control and FLAG-HA only cells, which 
was prevented by the addition of FLAG-HA-Survivin (Figure 3.4).  This confirms are 
intital Ki-67 data, showing that indeed the presence of tumor-released Survivin prohibits 
T lymphocyte proliferation in the presence of activating stimuli.    
Tertiary confirmation was done by a bromodeoxyuridine (BrdU) incorporation 
assay.  As cells replicate their DNA to prepare for division they incorporate the BrdU, 
which can be detected by flow cytometry.  We expected that in the presence of Survivin, 
the number of cells that have replicated their DNA for division and have become BrdU-
positive would be reduced if Survivin were indeed decreasing proliferation.  T 
lymphocytes were cultured with control medium or that containing FLAG and HA 
peptides or FLAG-HA-Survivin and BrdU added after 72 hours in culture.  Cells were 
harvested 24 hours later and analyzed for nuclear BrdU by flow cytometry.  T 
lymphocytes cultured with FLAG-HA-Survivin showed significantly reduced percentage 
of cells with BrdU incorporation (Figure 3.5).   
Final confirmation was done by cell counting by flow cytometry to determine if 
indeed a reduced number of cells was present due to this reduce proliferation observed by 
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our previous assays.  After culture and stimulation total T lymphocyte numbers were 
significantly decreased in FLAG-HA-Survivin cultures compared to controls (Figure 
3.6A).  Due to the fact that primary cells are far less resilient to the addition of exogenous 
materials than malignant cell lines, it was necessary to rule out cell death as a reason for 
this decreased proliferation and lower cell numbers.  To quantify cell death in our 
populations, we analyzed viability using 7-AAD staining and no significant difference in 
viability was seen in FLAG-HA-Survivin compared to controls (Figure 3.6B).  This data 
shows that Survivin has an anti-proliferative affect in T lymphocytes. 
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Figure 3.3. Representative gating scheme for CFSE analysis.  T lymphocytes were 
selected by their Forward and Side Scatter profiles and positive staining for CD3.  Helper 
and cytotoxic T lymphocyte populations were selected by CD4 and CD8 staining, 
respectively. 
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Figure 3.4. CFSE dilution in T lymphocytes.  A.  Plot of CFSE mean 
fluorescence intensity.  B. T lymphocytes have significantly decreased 
CFSE expression at 72 and 96 hours after activation in control conditions.  
CFSE dilution is reduced in cultures containing FLAG-HA-Survivin.  
**p<0.01, ***p<0.001. 
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Figure 3.5. BrdU incorporation in T lymphocytes.  A.  BrdU staining in CD4 and CD8 
T lymphocytes.  B.  T lymphocytes show decreased BrdU incorporation in the 
presence of Survivin compared to controls.  **p<0.01, ***p<0.001. 
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Figure 3.6. Cell number and viability analysis.  A.  Culture with Survivin results in 
decreased numbers of both CD4+ and CD8+ T lymphocytes upon stimulation with anti-
CD3/anti-CD28.  B.  Viability analysis by 7-AAD shows no increased cell death in T 
lymphocytes that are cultured with Survivin. 
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Survivin’s ability to prohibit proliferation in T lymphocytes is in stark contrast to 
the increased proliferative rate seen in malignant cells after Survivin uptake (Khan S et 
al. 2009).  One key difference between T lymphocytes and tumor cell proliferation is the 
requirement of activation signalling for T lymphocyte clonal expansion (Morris J and 
Waldmann T 2000; Song J et al. 2005).  Survivin’s anti-proliferative effect on T 
lymphocytes could be due to an interference with T cell activation.   
To examine this possibility, T lymphocytes were stimulated in the presence or 
absence of extracellular FLAG-HA-Survivin and analyzed for the expression of 
activation markers CD25 and CD69.  CD25, part of the high-affinity interleukin-2 (IL-2) 
receptor, is expressed on T lymphocytes after activation to aid in the response to the pro-
proliferative cytokine IL-2.  CD69 is an activation marker that is upregulated on the 
surface of T lymphocytes 2-4 hours after stimulation through CD3 signaling (Hamann J 
et al. 1993).  If Survivin is indeed interfering with the activation process, the expression 
of these two molecules that require stimulation for expression would be significantly 
reduced.  We found that the addition of FLAG-HA-Survivin during stimulation had no 
effect on the expression of activation antigens on T lymphocyte cultures (Figure 3.7).  
This data shows that Survivin’s anti-proliferative effects are not mediated by interfering 
with T cell activation through the T cell receptor-CD3 complex.   
T lymphocytes are one of the few adult tissues that normally express Survivin.  
Indeed, endogenous expression of Survivin is required for proper T cell activation and 
proliferation (Song J et al. 2005).  To determine if our exogenous FLAG-HA-Survivin 
was altering endogenous Survivin levels we measured Survivin expression in stimulated 
T lymphocytes in the presence of FLAG and HA peptides or FLAG-HA-Survivin by 
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Western blot.  The presence of exogenous FLAG-HA-Survivin does not significantly 
alter Survivin protein expression levels after activation (Figure 3.8).  From these results 
we conclude the inhibition of proliferation by Survivin likely occurs after cells have been 
activated and is not due to a reduction in activation-induced Survivin expression. 
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Figure 3.7.  Analysis of T lymphocyte activation.  A. Flow cytometric 
analysis of CD25 and CD69 activation markers after stimulation with 
anti-CD3/anti-CD28.  B. No significant difference in CD25 or CD69 
expression was seen in T lymphocytes after culture with Survivin.
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Figure 3.8. Western blot of Survivin expression in activated T lymphocytes.  The 
addition of FLAG-HA-Survivin to T lymphocyte cultures does not significantly affect 
the expression of endogenous Survivin after activation. 
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Conclusion 
Based on our data, we suggest that Survivin allows malignant cells to evade 
immune detection be decreasing the ability of T lymphocytes to proliferate in response to 
activating stimuli.  From the evaluation of activation markers CD25 and CD69, Survivin 
is not inhibiting T lymphocyte stimulation, but is possibly acting downstream of 
activation signaling.  Additionally, no changes in activation-induced endogenous 
Survivin in the presence of FLAG-HA-Survivin were observed.  Due to the significantly 
diminished proliferation observed in both CD4+ and CD8+ populations from cancer-free 
donors, we believe a similar effect would be seen in tumor-specific T lymphocyte and 
overall T lymphocyte populations from cancer patients, though these studies have yet to 
be accomplished. 
 
Materials & Methods 
Isolation of T Lymphocytes from Peripheral Blood 
Peripheral blood from normal, healthy donors was collected into potassium 
EDTA vacuettes as approved by the Institutional Review Board at Loma Linda 
University.  Peripheral blood mononuclear cells (PBMCs) were isolated from the buffy 
layer following centrifugation on a Ficoll-Hypaque gradient (GE Healthcare).  PBMCs 
were washed with cold Streptavidin Labeling Buffer (PBS with 2mM EDTA pH7.2) and 
stained with anti-human CD3 biotinylated antibodies (BioLegend) at 4°C.  Cells were 
again washed with cold Streptavidin Labeling Buffer and then incubated with 
Streptavidin magnetic microbeads. (Miltenyi Biotec)  After an additional wash the cells 
were added to a magnetic column and eluted from the CD3- cells.  The isolated CD3+ 
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cells were cultured in R10 medium (RPMI supplemented with 10% FBS, L-glutamine, 
penicillin/streptomycin, and 0.1% 2-mercaptoethanol). 
 
T Lymphocyte Proliferation Analysis by CFSE and Ki-67 
T lymphocytes were stained with 0.5 M CellTrace carboxyfluorescein 
succinimidyl ester (CFSE; Molecular Probes, Carlsbad, CA) for 15 min at 37C and the 
reaction quenched with 5 volumes of cold R10 medium (RPMI supplemented with 10% 
FBS, L-glutamine, penicillin/streptomycin, and 0.1% 2-mercaptoethanol).  Cells were 
plated in a 96-well plate at 2.5x105 cells/well in R10, FLAG-HA, or FLAG-HA-Survivin 
medium, stimulated with anti-CD3/anti-CD28 T cell expansion beads (6.25 μl/well; 
Invitrogen, Carlsbad, CA) and harvested at 0, 24, 48, 72, 96 and 120 hours.  Cells were 
stained for surface antigens CD3, CD4, CD8 and for viability using 7-AAD (BioLegend, 
San Diego, CA). For Ki-67 analysis cells were cultured as above and harvested at 24, 48, 
72, and 96 hours.  Cells were stained for surface markers, fixed and permeabilized using 
a Fixation/Permeabilization Kit (eBioscience, San Diego, CA) and stained for 
intracellular Ki-67. 
 
Analysis of T Lymphocyte Proliferation by BrdU Incorporation 
T cells were plated in a 96-well plate at 2.5x105 cells/well in R10, FLAG-HA, or 
FLAG-HA-Survivin medium and stimulated with anti-CD3/anti-CD28 T cell expansion 
beads (6.25 μl/well; Invitrogen, Carlsbad, CA).  At 72 hours in culture, 10 M BrdU was 
added to each well and the cells harvested 24 hours after BrdU addition.  Cells were 
stained for surface CD3, CD4 and CD8, fixed and permeabilized using BD 
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Cytofix/Cytoperm Buffer (BD Biosciences, San Jose, CA), and frozen at -80C overnight 
in freezing medium (10% DMSO, 90% heat-inactivated FBS).  Cells were thawed, 
washed using BD Cytofix/Cytoperm and then washed again with BD Perm/Wash Buffer, 
after which they were re-fixed as before.  Cells were treated with DNase (300g/ml) and 
stained with anti-BrdU FITC (BD Biosciences, San Jose, CA) before analysis on the 
MACSQuant flow cytometer.  
 
Analysis of T Lymphocyte Activation 
Isolated T lymphocytes were cultured and stimulated as described above.  After 
24 hours, cells were harvested and stained with monoclonal antibodies against CD3, 
CD4, CD8 (BioLegend, San Diego, CA), CD25 and CD69 (BD Biosciences, San Jose, 
CA) and analyzed by flow cytometry. 
 
Western Blotting 
To analyze Survivin expression after activation, T lymphocytes were cultured 
with control, FLAG-HA or FLAG-HA-Survivin medium and activated using anti-
CD3/anti-CD28 T cell expansion beads (25 μl/ml; Invitrogen, Carlsbad, CA).  Cells were 
harvested at 0, 24, 48, 72, and 96 hours.  Whole cell lysates were prepared and separated 
using 12% Bis-Tris polyacrylamide gels.  Proteins were transferred onto nitrocellulose 
membranes and probed using rabbit polyclonal anti-Survivin (Novus Biologicals, 
Littleton, CO) and rabbit polyclonal anti-Actin (Cell Signalling, Danvers, MA).  
Secondary IR-Dye conjugated goat anti-rabbit antibodies (LICOR, Lincoln, NE) were 
utilized and bands detected using the Odyssey imaging system (LICOR, Lincoln, NE).  
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CHAPTER FOUR 
ALTERATION OF CYTOTOXIC T LYMPHOCYTES BY 
SURVIVIN 
Introduction 
Peripheral blood and intratumoral T cells from cancer patients frequently exhibit 
altered T cell populations.  Cytotoxic T lymphocyte (CTL) function is frequently 
diminished as regulatory T cells (Tregs) increase and cytokine profiles are altered. Tregs 
are a subset of the helper T lymphocyte population and are characterized by their 
expression of the transcription factor Foxp3 (Chen W et al. 2003).  Their primary 
function is to prevent autoimmunity by inducing apoptosis or anergy in lymphocytes that 
recognized self-antigens.  Regulatory T cells have been implicated in promoting tumor 
growth by suppressing activation of tumor-specific cytotoxic T cells due to their 
expression of auto-antigens (Clarke SL et al. 2006; Sellitto A et al. 2011; Wang Z et al. 
2011; Yamagami W et al. 2011).  The balance of CTLs and Tregs in the tumor 
microenvironment is dependent partly on the cytokine environment, as increased levels of 
Transforming Growth Factor-β (TGF-β) induce naïve helper T cell differentiation into 
Tregs, which go on to reduce CTL cytotoxic numbers and functions (Chen W et al. 
2003).  Increased numbers of Tregs and decreased numbers of CTLs within the tumor 
correlates with poor prognosis and decreased responsiveness to immunotherapies (Ke X 
et al. 2008).  We hypothesize that Survivin can diminish cytotoxic T cell activity and 
numbers through modulation of the cytokine environment and the induction of regulatory 
T cells. 
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Results & discussion 
Cytotoxic Function in CD8+ T Lymphocytes 
Tumor-specific cytotoxic T lymphocytes (CTLs) are important in the destruction 
of cancer cells.  As described in chapter three, we have observed decreased proliferation 
of CTLs when stimulated in the presence of Survivin, which would likely diminish the 
effectiveness of an anti-cancer T lymphocyte response.  It is not known if Survivin also 
alters the cytotoxic function of CTLs, so we evaluated this using a cytotoxicity assay.  
CTLs were isolated from a single donor and cultured with Control, FLAG-HA or FLAG-
HA-Survivin medium and stimulated with PMA and ionomycin for 24 hours.  The cells 
were then added in culture with pooled peripheral blood mononuclear cells (PBMCs) 
from other healthy donors at 5:1, 2.5:1 and 1.25:1 CTL:PBMC ratios.  The ability of the 
CTLs to kill foreign PBMCs was then evaluated using by lactate dehydrogenase release.  
The cytotoxic function of CTLs was diminished at all CTL:PBMC ratios after culture 
with FLAG-HA-Survivin compared to control conditions (Figure 4.1).  This demonstrates 
a possible immune evasion function for tumor-released Survivin by preventing CTL-
mediated killing. 
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Figure 4.1. Cytotoxicity of CD8+ T lymphocytes.  Cytotoxic T lymphocyte cytolytic 
capabilities are reduced by pre-treatment with tumor-released Survivin. CD8+ cells 
from a single donor were cultured with Survivin for 24 h and their cytotoxic function 
assessed by the CytoTox 96 Non-Radioactive Cytotoxicity Assay.   *p<0.05 
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Regulatory T Lymphocyte Analysis 
Evaluation of Regulatory T Lymphocyte Induction 
 The reduction of cytotoxic function in CD8+ T lymphocytes in the presence of 
malignancy has been shown to be related to increased regulatory T lymphocytes (Treg) in 
the tumor microenvironment (Chikamatsu K et al. 2007; Ke X et al. 2008).  To determine 
if the decreased CTL function observed in the presence of Survivin could be due in part 
to Tregs, we evaluated the induction of Tregs after culture with Survivin.  CD3+ cells 
were cultured in control or Survivin containing medium with stimulation for 48 hours and 
analyzed for the number of CD4+CD25+CD127low Treg cells by flow cytometry.  No 
differences were seen in the number of Tregs in the presence of Survivin compared to 
controls (Figure 4.2). 
 
Regulatory T Lymphocyte Function 
To analyze the function of Tregs after culture with Survivin, CD4+CD127low 
Tregs were isolated by magnetic separation.  After 24 hours in culture with control, 
FLAG-HA, or FLAG-HA-Survivin medium, the cells were washed and plated with 
PBMCs and anti-CD3/anti-CD28 microbeads for 4 hours.  Analysis of CD154 and CD69 
levels on non-Treg cells was used to determine the ability of Tregs to suppress activation.  
We observed that Treg function was not altered by culture with tumor-released Survivin 
(Figure 4.3).  Due to these results, the decreased cytotoxic function of CD8+ cells is likely 
a direct effect of Survivin, and not through increased Treg numbers or function. 
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Figure 4.2.  Analysis of Regulatory T Lymphocytes  A. Gating 
scheme for regulatory T cells.  B. No significance difference in the 
amount of regulatory T cells was observed in the presence of 
Survivin. 
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Figure 4.3. Regulatory T Lymphocyte Function Assay.  
CD3+CD4+CD127low Treg suppression capability was evaluated by 
flow cytometry.  No significant difference in Treg function was seen 
between control and Survivin-treated cells. 
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Cytotoxic T Lymphocyte Subset Analysis 
Intracellular Cytokine Analysis 
 Although Survivin did not affect Treg function and numbers, CTL function was 
significantly altered.  The proportions of the subsets of cytotoxic T lymphocytes can have 
a dramatic affect on the inflammatory response to malignant cells.  Production of pro-
inflammatory cytokines like IFN- can enhance CTL function, while anti-inflammatory 
cytokines can suppress it.  The proportion of these cytokines is controlled in part by the 
proportion of type 1 and type 2 cytotoxic T lymphocytes.  Type 1 CTLs (Tc1) are 
characterized by their expression of IFN- and promote the overall cytotoxic functions of 
surrounding CTLs, while type 2 CTLs (Tc2) release cytokines that blunt CTL function.   
To evaluate the relative proportions of Tc1 and Tc2 cells we analyzed 
intracellular cytokine expression by flow cytometry.  Isolated T lymphocytes were 
cultured in control, FLAG-HA only or FLAG-HA-Survivin medium for 48 hours and 
then stimulated in the presence of cytokine release inhibitors.  After 6 hours of 
stimulation the cells were stained and evaluated for IFN-, IL-4, IL-5, and IL-13 
expression.  A significant reduction in CD8+IFN-+ Tc1 cells was seen after culture with 
Survivin, demonstrating a reduction in pro-inflammatory cells (Figure 4.4A,B).  
Additionally, CD8+ cells expressing the type 2 cytokines IL-5 and IL-13 increased 
substantially in FLAG-HA-Survivin cultures though the change in IL-4 expressing CD8+ 
cells was not significant (Figure 4.4B). 
 
Cytokine ELISA 
 To determine if the effects of Survivin on Tc1 and Tc2 numbers translates to 
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changes in overall cytokine release by cytotoxic T lymphocytes, we evaluated CTL 
cytokine release by ELISA.  Isolated CD8+ cells were stimulated with anti-CD3/anti-
CD28 microbeads for 48 hours and PMA and ionomycin added for the final 6 hours.  Cell 
supernatants were isolated and analyzed for IFN-, IL-2, IL-4, IL-5, IL-10 and IL-13 
release.  Analysis of the cytokine profile showed that pro-inflammatory Tc1 cytokines 
IFN- and IL-2 were dramatically reduced in Survivin treated cells (Figure 4.5), while 
Tc2 cytokines remained unchanged.  These changes in inflammatory cytokines may 
contribute to the decreased cytotoxic activity observed in the presence of Survivin. 
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Figure 4.4.  Flow Cytometric Analysis of Cytotoxic T Lymphocyte Subsets.  A.  
Gating scheme for CD8+ T cell subsets.  B. Survivin significantly decreases 
CD8+IFN-γ+ cell numbers and increases CD8+Il-5+ and CD8+IL-13+ cell numbers.  
***p<0.001. 
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Figure 4.5.   ELISA Analysis of Cytotoxic T Cell Cytokines.  Type 1 cytokines are 
decreased and Type 2 cytokines increased by Survivin.  Cytokine ELISA shows 
decreased production of inflammatory cytokines IFN-γ and IL-2 by CD8+ T cells.  No 
change was observed in anti-inflammatory IL-4, IL-5, IL-10 or IL-13 release. 
***p<0.001. 
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Conclusion 
 The results of our data show a decrease in cytotoxic activity in CTLs in the 
presence of isolated tumor-released Survivin.  While it was hypothesized that this was 
due to modulation of the regulatory T cell population, we found that Survivin had no 
significant effect on the numbers of Tregs, nor their ability to suppress activation in 
response to stimuli.  In contrast, it appears the effects on CTL cytotoxic function is more 
likely to be caused by a shifting of the cytotoxic T lymphocyte population in the presence 
of Survivin.  IFN-γ has been shown to enhance cytotoxic killing functions of CTLs in 
vitro and it is likely that the tremendous reduction in IFN-γ-producing cells and IFN-γ 
release induced by Survivin is responsible for the decrease in cytotoxic function we 
observed.  Additionally, a similar shift in Tc1 and Tc2 populations and cytokine release 
has been observed in cancer patients (Filella X et al. 2000; Ehi K et al. 2008).  The 
release of Survivin into the tumor microenvironment by malignant cells, while not 
altering the CTL:Treg balance, is likely hampering CTL function by pushing the immune 
response toward a type 2 and away from the type 1 response.  In addition to its anti-
proliferative functions in T cells, these findings show that Survivin is capable of altering 
the immune system towards a pro-tumor environment.   
 
Materials & Methods 
Analysis of CTL Cytotoxic Function 
CD8+ CTLs were isolated from a single healthy donor using the MACS anti-PE 
magnetic separation kit (Miltenyi Biotec, Auburn, CA) and anti-CD8 PE antibodies (BD 
Biosciences, San Jose, CA).  CTLs were cultured in 12-well plates in control, FLAG-HA 
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only or FLAG-HA-Survivin medium and stimulated with PMA (10ng/ml) and ionomycin 
(0.1μg/ml).  After 24 hours in culture the cells were washed and harvested.  Pooled 
PBMCs from various healthy donors were put into a 96-well plate with CTLs at 5:1, 
2.5:1, and 1.25:1 (CTL:PBMC) ratios.  The cytotoxic function of the CTLs was analyzed 
using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Fitchburg, WI), 
which measures the release of lactate dehydrogenase upon cell lysis. 
 
Regulatory T Lymphocyte Analysis 
CD3+ T lymphocytes were isolated and plated in 96-well in control, FLAG-HA 
only or FLAG-HA-Survivin medium and stimulated for 48 hours with anti-CD3/anti-
CD28 T cell expansion beads (6.25μl/well; Invitrogen, Carlsbad, CA).  Cells were stained 
for CD3, CD4, CD8 (BioLegend, San Diego, CA), CD25 and CD127 (BD Biosciences, 
San Jose, CA) and CD4+CD25+CD127low Treg populations analyzed by flow cytometry. 
 
Regulatory T Lymphocyte Activity Assay 
T regulatory cells were isolated from PBMCs using the EasySep Human 
CD4+CD127low T Cell Enrichment Kit (Stem Cell Technologies, Vancouver, BC, 
Canada) and cultured in 12-well plates at 1x106 cells/ml in control, FLAG-HA, or FLAG-
HA-Survivin medium.  After 24 hours, cells were washed, harvested and added to 
PBMCs at a 0:1, 0.25:1 or 0.5:1 (Treg:PBMC) concentration.  Inhibition of cell activation 
by Tregs was evaluated using the BD FastImmune Human Regulatory T Cell Function 
Kit (BD Biosciences, San Jose, CA) and measuring the suppression of CD154 and CD69 
induction by flow cytometry. 
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Intracellular Cytokine Analysis 
CD3+ T lymphocytes were isolated, plated in 96-well plates as described above 
and stimulated with PMA (10ng/ml) and ionomycin (0.1μg/ml) in the presence of 3 μM 
monensin to inhibit cytokine release.  After 6 hours of activation, the cells were harvested 
and stained for T lymphocyte surface markers.  Cells were fixed and permeabilized and 
intracellularly stained with biotinylated antibodies against IFN-γ, IL-4, IL-5, or IL-13 
followed by streptavidin-APC (eBioscience, San Diego, CA).  Stained cells were 
evaluated using the MACSQuant flow cytometer. 
 
Cytokine ELISA 
Isolated CD8+ cells were stimulated with anti-CD3/anti-CD28 microbeads for 48 
hours and PMA and ionomycin added for the final 6 hours.  Cell supernatants were 
isolated and analyzed using Ready-Set-Go! ELISAs (eBioscience) for concentrations of 
IFN- γ, IL-2, IL-4, IL-5, IL-10, and IL-13. 
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CHAPTER FIVE 
ALTERATION OF HELPER T LYMPHOCYTES BY 
SURVIVIN 
Introduction 
The tumor microenvironment is characterized by the infiltration of T cells (Liao Y 
et al. 2007; Whiteside TL 2008).  Investigation into the role of T cells in tumor 
progression has demonstrated the importance of the inflammatory T cell response in 
elimination of neoplastic cells (Hamai A et al. 2010).  The importance of T cell subsets in 
the anti-tumor response is of interest as imbalances in these cells and the cytokines they 
produce have been shown to alter the ability of the immune system to eradicate the tumor 
(Whiteside TL 2008).  Of particular interest are the type 1 and type 2 T cells, which are 
characterized by production of IFN-γ and IL-2 or IL-4 and IL-10, respectively (Zhu J and 
Paul WE 2008).  
Peripheral blood and intratumoral T cells from cancer patients frequently exhibit 
altered T cell populations.  Type 1 responses are typically decreased with a concomitant 
increase in type 2 cell numbers and cytokine levels (Filella X et al. 2000; Ito N et al. 
2001; Mainou-Fowler T et al. 2003; Ehi K et al. 2008). The potential for metastasis and 
angiogenesis is increased by the presence of IL-4 and IL-6, respectively, and the type 2 
polarization increases both of these cytokines (Naldini A et al. 2003; DeNardo DG et al. 
2009).  This shift is correlated to poor disease progression, as the anti-tumor response is 
inhibited and a pro-tumor environment is created (Filella X et al. 2000; Murakami H et 
al. 2004; Ehi K et al. 2008).  Th17 cells, which release pro-inflammatory cytokines IL-17 
and IL-21, have been implicated in the progression of malignancy in prostate and 
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colorectal cancers(Liu J et al. 2011) (Sfanos KS et al. 2008).  However, in breast cancer a 
reduced number of Th17 cells is linked to poor prognosis (Yang L et al. 2012).  The 
exact role of these cells in tumor progression seems to be cancer-type specific.  While 
altered T cell populations in the tumor have been well documented from a clinical aspect, 
what leads to these changes has not been fully elucidated.  Here we propose that Survivin 
could play a role in this helper T lymphocyte shift to a predominately type 2 phenotype. 
 
Results & Discussion 
Helper T Lymphocyte Subset Analysis 
Intracellular Cytokine Analysis 
After 6 hours of stimulation the cells were stained and evaluated for IFN-, IL-4, 
IL-5, and IL-13 expression.  A significant reduction in CD8+IFN-+ Tc1 cells was seen 
after culture with Survivin, demonstrating a reduction in pro-inflammatory cells (Figure 
4.4A,B).  Additionally, CD8+ cells expressing the type 2 cytokines IL-5 and IL-13 
increased substantially in FLAG-HA-Survivin cultures though the change in IL-4 
expressing CD8+ cells was not significant (Figure 4.4B). 
To evaluate the effects of tumor-released Survivin in T cell population skewing, 
intracellular cytokine staining was used to quantify the number of Th1, Th2, and Th17 
cells (Figure 5.1).  Isolated T lymphocytes were cultured in control, FLAG-HA only or 
FLAG-HA-Survivin medium for 48 hours and then stimulated in the presence of cytokine 
release inhibitors.  Figure 5.1A shows representative gating of intracellular cytokine 
analysis for CD4+ T cells.  As was observed in the cytotoxic T cell population, numbers 
of Th1 (CD4+IFN-+) cells were significantly decreased in Survivin-containing cultures 
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(Figure 5.1B).  Additionally, Th2 cells expressing the cytokines IL-4, IL-5 and IL-13 
increased substantially in FLAG-HA-Survivin cultures (Figure 5.1B).  Evaluation of 
Th17 cells by expression of IL-17 showed no difference in cell numbers in the presence 
of Survivin (Figure 5.2).  Due to the variable role of Th17 cells in cancer it is not 
surprising that the ubiquitously expressed Survivin does not have a substantial affect on 
this cell population.     
 
Cytokine ELISA 
To determine if this adjustment in cell numbers correlates to changes in cytokine 
release, isolated CD4+ cells were plated in control, FLAG-HA only or FLAG-HA-
Survivin medium for 48 hours, and the culture supernatants evaluated by ELISA (Figure 
5.3).  Production of the Th1 cytokines IFN- and IL-2 was significantly reduced, which 
correlates well with our observation that Th1 cell numbers were significantly reduced in 
Survivin-containing cultures.   Because IFN- is necessary for perpetuating the 
differentiation of naïve T cells into Tc1 and Th1 cells, this reduction in IFN- could 
enhance what we previously observed in the cytotoxic T cells, resulting in blunted 
cytotoxic activity of CTLs.  Additionally, the significant drop in IL-2 could play a part in 
the decreased proliferation following activation of T cells, as IL-2 is necessary in 
inducing cell division and clonal expansion of activated T cells. 
 Secretion of the Th2 cell cytokines showed variable changes in release after 
culture with Survivin.  Although the number of cells expressing IL-4, IL-5 and IL-13 all 
increased based on intracellular cytokine flow cytometry, only the quantities of IL-4 and 
IL-13 release was significantly increased when cultured with FLAG-HA-Survivin (Figure 
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5.3).  No significant change was seen in IL-5 or IL-10 levels (Figure 5.3).  This shows 
that Survivin does mediate a shift toward a Th2-dominant population, but does not 
increase the levels of all Th2 cytokines.  
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Figure 5.1.  Flow Cytometric Analysis of Helper T Lymphocyte Subsets.  A.  Gating 
scheme for CD4+ T cell subsets.  B. Survivin significantly decreases CD4+IFN-γ+ 
cell numbers and increases CD4+Il-5+, CD4+IL-13+, and CD4+IL-4+ cell numbers. 
*p<0.05, **p<0.01 and ***p<0.001. 
 
 
68 
 
 
 
 
 
Figure 5.2.  Analysis of IL-17 expression in T lymphocytes.  A.  Representative gating 
scheme. B. Percent IL-17 expressing CD4+ T lymphocytes were not altered in the 
presence of FLAG-HA-Survivin. 
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Figure 5.3.  ELISA Analysis of Helper T Cell Cytokines. Type 1 cytokines are decreased 
and Type 2 cytokines increased by Survivin.  Cytokine ELISA shows decreased 
production of inflammatory cytokines IFN-γ and IL-2 by CD4+ T cells and increased IL-
4 and IL-13 production in the presence of Survivin.  No change was observed in IL-5 or 
IL-10 release. *p<0.05, **p<0.01 and ***p<0.001. 
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Conclusion 
Alteration of the immune response toward the type 2 phenotype has been 
demonstrated in many types of cancer, including lymphoma, breast, prostate and lung 
cancer.  Despite this important role in clinical malignancy the mechanism behind this 
shift has remained elusive.  In these studies we showed that the polarization of the helper 
T cell response leading to a hindered pro-inflammatory response could be mediated by 
tumor-released Survivin.  The overall shift from a type 1 to a type 2 response was shown 
both by the decrease in IFN-γ+ T cells and the increase in IL-4+, IL-5+ and IL-13+ T cells 
in response to Survivin. These findings demonstrate a role for Survivin in mediating the 
shift from a type 1 to a type 2 T cell response in the tumor microenvironment. 
 
Materials & Methods 
Intracellular Cytokine Analysis 
CD3+ T lymphocytes were isolated, plated in 96-well plates in control, FLAG-HA 
only or FLAG-HA-Survivin medium and stimulated with PMA (10ng/ml) and ionomycin 
(0.1μg/ml) in the presence of 3 μM monensin to inhibit cytokine release.  After 6 hours of 
activation, the cells were harvested and stained for T lymphocyte surface markers.  Cells 
were fixed and permeabilized and intracellularly stained with biotinylated antibodies 
against IFN-γ, IL-4, IL-5, IL-13, or IL-17 followed by streptavidin-APC (eBioscience, 
San Diego, CA).  Stained cells were evaluated using the MACSQuant flow cytometer. 
 
Cytokine ELISA 
Isolated CD4+ cells were stimulated with anti-CD3/anti-CD28 microbeads for 48 
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hours and PMA and ionomycin added for the final 6 hours in the presence or absence of 
Survivin.  Cell supernatants were isolated and analyzed using Ready-Set-Go! ELISAs 
(eBioscience) for concentrations of IFN- γ, IL-2, IL-4, IL-5, IL-10, IL-13 and IL-17. 
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CHAPTER SIX 
CONCLUSIONS 
Summary of Findings 
 Our studies isolated FLAG-HA tagged Survivin released from malignant cells and 
characterized its effects on normal T lymphocytes.  Evaluation of Survivin’s effects on T 
cells demonstrated its ability to diminish their proliferation without altering their ability 
to be activated by the proper stimuli.  Additionally, Survivin diminishes cytotoxic T cell 
function by altering the cytokine environment.  The large reduction in inflammatory T 
cells and cytokines, as well as the increase in type 2 T cells by Survivin coincides with 
what has been seen in cancer patients and supports our hypothesis that extracellular 
Survivin acts as an immune mediator.  From our data we can conclude that: 1) 
Extracellular Survivin can bind to and be taken up into normal T lymphocytes; 2) Uptake 
of Survivin diminishes clonal expansion of T lymphocytes; and 3) Survivin shifts the T 
cell population toward a type 2 phenotype, but does not alter the regulatory T or Th17 
populations.   
 
Tumor-Released Survivin Alters the T Lymphocyte Population 
In chapter 2 we demonstrated that the tumor-released protein Survivin could be 
isolated from conditioned medium, and upon addition to T cell cultures, is able to bind to 
and be taken up by T cells.  Like that described by Mera et al. (2008) using recombinant 
protein, tumor-released Survivin is able to bind to the surface of T cells, and as 
demonstrated in our studies, is also taken up into T cells.  This data supports our 
hypothesis that Survivin uptake could occur within the tumor microenvironment as a 
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means of modulating T lymphocyte function.  The inhibition of T lymphocyte division by 
Survivin detailed in chapter 3 is in contrast to its effects on malignant cells (Khan S et al. 
2009).  While in malignant cells uptake of Survivin induced proliferation, T cell division 
is hindered.  Based on the evaluation of activation markers CD25 and CD69, Survivin is 
not inhibiting T cell stimulation, but is possibly acting downstream of activation 
signaling.  Additionally, no changes in activation-induced endogenous Survivin in the 
presence of FLAG-HA-Survivin were observed.  As discussed in chapters 4 and 5, the 
dramatic changes in IL-2 production in the presence of Survivin it is possible that the 
mechanism of decreased proliferation is related to cytokine effects.   
In addition to their decreased proliferative capacity, Survivin-exposed CD8+ T 
cells exhibited decreased cytotoxic function compared to controls.  Many previous 
studies have demonstrated the inhibition of tumor-specific CTL function by T regulatory 
(Treg) cells (Chattopadhyay S et al. 2006; James E et al. 2010).  However in our studies, 
Survivin did not significantly alter Treg numbers or function.  Because of these 
observations, we hypothesize that Survivin’s inhibition of cytotoxic function is 
independent of Treg-mediated CTL suppression.   Based on our data in chapters 4 and 5, 
we believe changes to the cytokine profile and decreased IFN-γ production is likely 
responsible for this suppression.  The release of Survivin may be one mechanism by 
which tumors evade T cell-mediated cytotoxicity.   
Although Treg populations were not affected by extracellular Survivin, type 1 and 
type 2 T cell populations were significantly altered.  The decrease in IFN-γ and IL-2 
production by T cells, combined with the significant drop in IFN-γ+ cells demonstrates an 
inhibition of the anti-tumor response.  The importance of IFN-γ to immune surveillance 
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has been shown previously in spontaneous malignancy in IFN-γ deficient mice.  
Additionally, it is frequently decreased in cancer patients (Filella X et al. 2000; Ellyard JI 
et al. 2007; Ehi K et al. 2008; Hamai A et al. 2010).  The overall shift from a type 1 to a 
type 2 response was shown both by the decrease in IFN-γ+ T cells and the increase in IL-
4+, IL-5+ and IL-13+ T cells in response to tumor-released Survivin.   
The importance of CD4+IL-4+cells in malignancy was recently demonstrated in a 
mouse mammary carcinoma model, in which production of IL-4 by helper T cells was 
able to polarize macrophages, resulting in increased lung metastasis (DeNardo DG et al. 
2009).  Similarly, increased plasma levels of IL-13 in patients with pancreatic, gastric and 
esophageal cancers was positively correlated to increased numbers of myeloid derived 
suppressor cells (Gabitass RF et al. 2011).  Both these studies showed important 
downstream effects of the shift to a type 2 response, but did not examine the preliminary 
cause of the shift.  Importantly, when combined with this study and our previous work 
showing Survivin-associated invasiveness (Khan S et al. 2009), a more complete picture 
emerges with Survivin inducing the type 2 response, which can then lead to increased 
metastasis and complete polarization of the immune response.   
Alteration of the immune response toward the type 2 phenotype has been 
demonstrated in many types of cancer, including lymphoma, breast, prostate and lung 
cancer, though the reason for this shift was undetermined (Filella X et al. 2000; 
Nakayama H et al. 2000; Ito N et al. 2001; Mainou-Fowler T et al. 2003; Ehi K et al. 
2008).  Similar studies have been performed looking at Th17 cells in cancer patients 
(Sfanos KS et al. 2008; Kryczek I et al. 2009; Yang ZZ et al. 2009; Maniati E et al. 
2010).  Unlike the Th1/Th2 shift, which is common across patients with a variety of 
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cancer types, the role of Th17 cells appear to be cancer-type specific.  In prostate and 
ovarian cancers, increased numbers of Th17 cells in the tumor correlated with better 
patient outcome, demonstrating an anti-tumor role (Sfanos KS et al. 2008; Kryczek I et 
al. 2009).  Conversely, in colorectal carcinoma, higher levels of serum IL-17 correlated 
to poor patient prognosis (Liu J et al. 2011).  In our studies, no change in IL-17-
expressing cells was observed after exposure to Survivin (Supplementary Figure 7), 
unlike our observed type 1 and type 2 T cell shift.   
 
Clinical Implications 
In this study we show that the polarization of the T cell response leading to a pro-
tumor response could be mediated in part by tumor-released Survivin.  The ability of 
Survivin to decrease the proliferation and cytotoxicity of T cells and alter the T cell 
response to malignant cells, as well as positively affect tumor growth and aggressiveness, 
makes it an important therapeutic target for the treatment of cancer. 
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